Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the pre…
| Métrica | CUVL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.7% | — |
| Operating Margin | — | -31.5% | — |
| Net Margin | — | -30.4% | — |
| FCF Margin | — | -10.6% | — |
| ROE | — | -36.3% | — |
| ROA | — | -30.0% | — |
| Current Ratio | — | 2.68 | — |
| Debt / Equity | — | 0.28 | — |
Clinuvel Pharmaceuticals Ltd cotiza a 5.15 USD y tiene una capitalización bursátil de $260M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud